Dimed Distribuidora de Medicamentos Balance Sheet Health
Financial Health criteria checks 4/6
Dimed Distribuidora de Medicamentos has a total shareholder equity of R$1.3B and total debt of R$600.9M, which brings its debt-to-equity ratio to 46.2%. Its total assets and total liabilities are R$3.7B and R$2.4B respectively. Dimed Distribuidora de Medicamentos's EBIT is R$271.7M making its interest coverage ratio 2.8. It has cash and short-term investments of R$304.0M.
Key information
46.22%
Debt to equity ratio
R$600.94m
Debt
| Interest coverage ratio | 2.8x |
| Cash | R$304.00m |
| Equity | R$1.30b |
| Total liabilities | R$2.36b |
| Total assets | R$3.66b |
Recent financial health updates
Analysis Article • Jul 12
These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Mar 25
Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Recent updates
Narrative Update • May 01
PNVL3: Steady Fair Value Will Support Bullish Rerating Into 2026 Meeting
Analysts kept their fair value estimate for Dimed Distribuidora de Medicamentos steady at R$18.80, with a slightly higher discount rate and marginally adjusted revenue growth, profit margin, and future P/E inputs guiding the updated price target view. What's in the News Dimed S.A. Distribuidora de Medicamentos has scheduled a Special and Extraordinary Shareholders Meeting for April 30, 2026.Narrative Update • Apr 15
PNVL3: Steady Fair Value Will Support Bullish Rerating Into 2026 Meeting
Analysts have maintained their R$18.80 price target for Dimed Distribuidora de Medicamentos, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions that support this reaffirmed view. What's in the News Dimed Distribuidora de Medicamentos has scheduled a Special and Extraordinary Shareholders Meeting for April 30, 2026, in Eldorado do Sul, Rio Grande do Sul, at Avenida Industrial Belgraf 865.Narrative Update • Apr 01
PNVL3: Steady Fair Value And Slight Assumption Shifts Will Support Bullish Rerating
Analysts have maintained the price target for Dimed Distribuidora de Medicamentos at R$18.80, noting only minor adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially affect their valuation view. Valuation Changes Fair Value: R$18.80 remains unchanged, indicating no revision to the central valuation estimate.Analysis Article • Mar 27
Shareholders Can Be Confident That Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Earnings Are High Quality
Dimed S.A. Distribuidora de Medicamentos ( BVMF:PNVL3 ) just reported healthy earnings but the stock price didn't move...Narrative Update • Mar 09
PNVL3: Higher Assumed Margins And P/E Will Support Bullish ReRating
Analysts have raised their fair value estimate for Dimed Distribuidora de Medicamentos from R$14.20 to R$18.80. This change reflects updated assumptions for revenue growth, profit margins and future P/E multiples.Narrative Update • Feb 23
PNVL3: Elevated P/E Assumptions Will Sustain Bearish Fair Value View
Analysts kept their price target for Dimed Distribuidora de Medicamentos steady at R$14.20, with only small tweaks to the discount rate, long term revenue growth, profit margin assumptions and future P/E estimates shaping this narrative update. Valuation Changes Fair Value: R$14.20 remains unchanged, suggesting no adjustment to the central valuation anchor.Analysis Article • Feb 12
Why Investors Shouldn't Be Surprised By Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) 26% Share Price Surge
Dimed S.A. Distribuidora de Medicamentos ( BVMF:PNVL3 ) shares have continued their recent momentum with a 26% gain in...Narrative Update • Feb 09
PNVL3: Future Margins And P/E Assumptions Will Guide Fair Outlook
Analysts have lifted their fair value estimate for Dimed Distribuidora de Medicamentos from R$13.00 to R$14.20, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. Valuation Changes Fair Value: updated from R$13.00 to R$14.20, indicating a modest upward revision in the intrinsic value estimate.Narrative Update • Jan 26
PNVL3: Future Profitability And P/E Assumptions Will Shape Fair Outlook
Analysts have raised their price target for Dimed Distribuidora de Medicamentos from R$11.90 to R$13.00, citing model updates that reflect revised assumptions for discount rate, revenue growth, profit margin, and future P/E levels. Valuation Changes Fair Value: Price target revised from R$11.90 to R$13.00, representing a modest upward adjustment in the estimated share value.Analysis Article • Dec 19
What You Can Learn From Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) P/E
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 9x, you may consider Dimed...Analysis Article • Nov 29
Does Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Jun 20
Capital Allocation Trends At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Narrative • Mar 13
Digital Strategy And AI Investments Will Improve Efficiency In Pharma Retail
Panvel's digital strategy and investment in AI tools boost sales and improve margins through increased efficiencies and tech-savvy customer engagement.Analysis Article • Nov 17
Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Dimed S.A. Distribuidora de Medicamentos ( BVMF:PNVL3 ) came out with its third-quarter results last week, and we...Analysis Article • Nov 04
Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...Analysis Article • Jul 12
These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 27
Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings
Dimed S.A. Distribuidora de Medicamentos' ( BVMF:PNVL3 ) stock was strong after they reported robust earnings. However...Analysis Article • Apr 15
Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Analysis Article • Mar 25
Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jan 06
The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Analysis Article • Oct 23
Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
To the annoyance of some shareholders, Dimed S.A. Distribuidora de Medicamentos ( BVMF:PNVL3 ) shares are down a...Analysis Article • Aug 15
Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Financial Position Analysis
Short Term Liabilities: PNVL3's short term assets (R$2.1B) exceed its short term liabilities (R$1.2B).
Long Term Liabilities: PNVL3's short term assets (R$2.1B) exceed its long term liabilities (R$1.2B).
Debt to Equity History and Analysis
Debt Level: PNVL3's net debt to equity ratio (22.8%) is considered satisfactory.
Reducing Debt: PNVL3's debt to equity ratio has increased from 18.4% to 46.2% over the past 5 years.
Debt Coverage: PNVL3's debt is well covered by operating cash flow (75%).
Interest Coverage: PNVL3's interest payments on its debt are not well covered by EBIT (2.8x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/17 02:48 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dimed S.A. Distribuidora de Medicamentos is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Frederico Mendes | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Francisco Navarrete | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |